Baker Bros. Advisors LP Replimune Group, Inc. Transaction History

Baker Bros. Advisors LP

$9.02 Billion
Q4 2024

A detailed history of Baker Bros. Advisors LP transactions in Replimune Group, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 11,045,336 shares of REPL stock, worth $140 Million. This represents 1.48% of its overall portfolio holdings.

Number of Shares

11,045,336

Previous 11,045,336 -0.0%

Holding current value

$140 Million

Previous $121 Million 10.49%

% of portfolio

1.48%

Previous 1.3%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$8.09 - $11.23 $8.09 Million - $11.2 Million	1,000,000 Added 9.95%	11,045,336 $121 Million
Q2 2024 Aug 14, 2024	BUY	$5.01 - $9.46 $2.51 Million - $4.73 Million	500,000 Added 5.24%	10,045,336 $90.4 Million
Q4 2023 Feb 14, 2024	BUY	$6.75 - $16.18 $33.5 Million - $80.4 Million	4,967,056 Added 108.49%	9,545,336 $80.5 Million
Q4 2022 Feb 14, 2023	BUY	$17.09 - $27.91 $11.7 Million - $19.1 Million	684,437 Added 17.58%	4,578,280 $125 Million
Q3 2022 Nov 14, 2022	BUY	$15.6 - $21.15 $4.72 Million - $6.4 Million	302,762 Added 8.43%	3,893,843 $67.2 Million
Q2 2022 Aug 15, 2022	BUY	$13.32 - $19.98 $26.4 Million - $39.5 Million	1,979,378 Added 122.81%	3,591,081 $62.8 Million
Q1 2022 May 16, 2022	BUY	$15.24 - $29.75 $15.5 Million - $30.3 Million	1,018,308 Added 171.61%	1,611,703 $27.4 Million
Q4 2021 Feb 14, 2022	BUY	$25.43 - $34.25 $11.2 Million - $15.1 Million	439,883 Added 286.55%	593,395 $16.1 Million
Q4 2020 Feb 16, 2021	SELL	$23.5 - $52.65 $1.25 Million - $2.79 Million	-53,074 Reduced 25.69%	153,512 $5.86 Million
Q3 2020 Nov 16, 2020	BUY	$18.85 - $27.0 $3.8 Million - $5.44 Million	201,445 Added 3918.4%	206,586 $4.76 Million
Q2 2020 Aug 14, 2020	BUY	$9.76 - $25.95 $50,176 - $133,408	5,141 New	5,141 $128,000

Others Institutions Holding REPL

# of Institutions

161

Shares Held

74.9M

Call Options Held

38.4K

Put Options Held

43.7K

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $625M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.

Account

Baker Bros. Advisors LP Replimune Group, Inc. Transaction History